Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00049036 · OUTCOME

Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment

Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma · Source last updated 2014-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion
Interval / dispersion
Not reported
Time frame
60 days

What was measured

Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma

Analysis population: ITT

Groups in this outcome

EPOCH + Concurrent Rituximab

Patients receive rituximab IV over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.

EPOCH Followed by Rituximab

Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
EPOCH + Concurrent Rituximab51
EPOCH Followed by Rituximab55

Reported measurements

Source class 1
Values in proportion · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EPOCH + Concurrent Rituximab0.69Not reportedNot reportedNot reportedNot reported
EPOCH Followed by Rituximab0.53Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0.69
      2. group Id
        OG001
        value
        0.53
denoms
  1. counts
    1. group Id
      OG000
      value
      51
    2. group Id
      OG001
      value
      55
    units
    Participants
description
Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma
groups
  1. description
    Patients receive rituximab IV over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.
    id
    OG000
    title
    EPOCH + Concurrent Rituximab
  2. description
    Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.
    id
    OG001
    title
    EPOCH Followed by Rituximab
param Type
NUMBER
population Description
ITT
reporting Status
POSTED
time Frame
60 days
title
Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment
type
PRIMARY
unit Of Measure
proportion

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice